NASDAQ:VSTM

Verastem (VSTM) Stock Price, News & Analysis

$11.50
-0.63 (-5.19%)
(As of 05/17/2024 ET)
Today's Range
$11.34
$12.16
50-Day Range
$9.22
$13.16
52-Week Range
$4.74
$15.18
Volume
137,643 shs
Average Volume
135,216 shs
Market Capitalization
$291.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.79

Verastem MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
150.3% Upside
$28.79 Price Target
Short Interest
Bearish
3.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.64mentions of Verastem in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$6,619 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.16) to ($2.73) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.33 out of 5 stars

Medical Sector

573rd out of 922 stocks

Pharmaceutical Preparations Industry

265th out of 425 stocks

VSTM stock logo

About Verastem Stock (NASDAQ:VSTM)

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

VSTM Stock Price History

VSTM Stock News Headlines

HC Wainwright Reiterates Buy Rating for Verastem (NASDAQ:VSTM)
Verastem (NASDAQ:VSTM) Raised to Hold at StockNews.com
VSTM Stock Earnings: Verastem Beats EPS for Q1 2024
Arrowhead Research: Fiscal Q2 Earnings Snapshot
Verastem, Inc. (VSTM)
VSTM Apr 2024 11.000 call
VSTM Apr 2024 14.000 call
Recap: Verastem Q4 Earnings
See More Headlines
Receive VSTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/14/2024
Today
5/17/2024
Next Earnings (Estimated)
8/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VSTM
CUSIP
92337C10
Fax
N/A
Employees
73
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$28.79
High Stock Price Target
$36.00
Low Stock Price Target
$17.50
Potential Upside/Downside
+150.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-87,370,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.60 million
Book Value
$0.99 per share

Miscellaneous

Free Float
24,769,000
Market Cap
$291.30 million
Optionable
Optionable
Beta
0.58
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Daniel W. Paterson (Age 63)
    President, CEO & Director
    Comp: $697.98k
  • Mr. Daniel Calkins (Age 36)
    CFO and Principal Accounting & Financial Officer
    Comp: $1.42M
  • Mr. Richard H. Aldrich M.B.A. (Age 70)
    Founder and Consultant
    Comp: $38.39k
  • Dr. Robert A. Weinberg Ph.D.
    Co-Founder & Chair of Scientific Advisory Board
  • Dr. Piyush B. Gupta Ph.D.
    Co-Founder
  • Dr. Michelle Dipp M.D. (Age 48)
    Ph.D., Co-Founder
  • Mr. Robert Pintar M.B.A.
    Senior Vice President of Technical Operations
  • Dr. Jonathan Pachter Ph.D. (Age 66)
    Chief Scientific Officer
    Comp: $238.18k
  • Mr. Nate Sanburn
    Senior Vice President of Corporate Development & External Engagement
  • Dr. Hagop Youssoufian M.D. (Age 67)
    M.Sc., Ph.D., Head of Medical Strategy

VSTM Stock Analysis - Frequently Asked Questions

Should I buy or sell Verastem stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VSTM shares.
View VSTM analyst ratings
or view top-rated stocks.

What is Verastem's stock price target for 2024?

6 equities research analysts have issued 12 month price objectives for Verastem's stock. Their VSTM share price targets range from $17.50 to $36.00. On average, they predict the company's share price to reach $28.79 in the next twelve months. This suggests a possible upside of 150.3% from the stock's current price.
View analysts price targets for VSTM
or view top-rated stocks among Wall Street analysts.

How have VSTM shares performed in 2024?

Verastem's stock was trading at $8.14 at the start of the year. Since then, VSTM stock has increased by 41.3% and is now trading at $11.50.
View the best growth stocks for 2024 here
.

When is Verastem's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our VSTM earnings forecast
.

How were Verastem's earnings last quarter?

Verastem, Inc. (NASDAQ:VSTM) released its earnings results on Thursday, March, 14th. The biopharmaceutical company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.82) by $0.20.

When did Verastem's stock split?

Verastem's stock reverse split before market open on Thursday, June 1st 2023. The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is Robert Forrester's approval rating as Verastem's CEO?

11 employees have rated Verastem Chief Executive Officer Robert Forrester on Glassdoor.com. Robert Forrester has an approval rating of 100% among the company's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Verastem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Amarin (AMRN) and Viking Therapeutics (VKTX).

Who are Verastem's major shareholders?

Verastem's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.59%) and Cannon Global Investment Management LLC (0.04%). Insiders that own company stock include Brian M Stuglik, Dan Paterson, Daniel Calkins and Robert E Gagnon.
View institutional ownership trends
.

How do I buy shares of Verastem?

Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VSTM) was last updated on 5/17/2024 by MarketBeat.com Staff

From Our Partners